Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Withdrawn 1No longer available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Glioma 1Glioblastoma 1

Interventions

Temozolomide 9Magnetic Resonance Spectroscopy 9Bevacizumab 8Radiotherapy 4Radiation 4Lomustine 3Carmustine 3pembrolizumab 2dexamethasone acetate 2atezolizumab 2TIC10 compound 2Surgical Procedures, Operative 2Sunitinib 2Standard of Care 2Specimen Handling 2Sorafenib 2Radiosurgery 2Irinotecan 2Dexamethasone 2Carboplatin 2Calcium Dobesilate 2Axitinib 2Aminolevulinic Acid 2vocimagene amiretrorepvec 1tandutinib 1poly ICLC 1pazopanib 1niraparib 1keyhole-limpet hemocyanin 1gallium Ga 68 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Glioblastoma × Adjuvants, Immunologic × Clear all
NCT02754362 2020-01-13

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

NYU Langone Health

Phase 2 Withdrawn
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡